Drug news

CHMP recommends Caprelsa (AstraZeneca) for Thyroid Cancer

Read time: 1 mins

Last updated:18th Nov 2011

Published:18th Nov 2011

Source: Pharmawand

The CHMP has recommended vandetanib, as Caprelsa from AstraZeneca for the treatment of advanced, aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease, a rare form thyroid cancer. Previously the drug was known as Zactima. The drug has been approved by the FDA and the decision was based on the ZETA study.

Learning Zone Homepage

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news